Rethinking Outflow in Glaucoma: The Role of Nitric Oxide (CE Webcast)
Activity Description and Purpose
New additions to the glaucoma treatment arsenal can result in better outcomes for patients with glaucoma and ocular hypertension. Optometrists who treat these patients need to keep abreast of how new these treatments work and determine how best to incorporate them into clinical practice on the basis of evidence from pivotal clinical trials.
The goals of this activity are to help optometrists better understand the influences of nitric oxide on the trabecular meshwork and to integrate new therapy based on safety and efficacy in preventing glaucoma progression.
This educational activity is intended for optometrists.
After completing this activity, participants will be better able to:
- Describe the downstream signaling effects of nitric oxide in relation to glaucoma
- Discuss the effects of nitric oxide on the trabecular meshwork
- Apply data from clinical trials on nitric oxide–donating agent(s) for lowering intraocular pressure
|Murray Fingeret, OD, FAAO (Chair)|
State University of New York College of Optometry
New York, New York
|Michael Chaglasian, OD, FAAO|
Chief of Staff
Illinois Eye Institute
Illinois College of Optometry
|Louis R. Pasquale, MD, FARVO|
Professor of Ophthalmology
Icahn School of Medicine at Mount Sinai
Site Chair, Department of Ophthalmology
The Mount Sinai Hospital and Mount Sinai Queens
Deputy Chair, Ophthalmology Research
Director, Eye and Vision Research Institute
Mount Sinai Health System
New York, New York
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Michael Chaglasian, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Alcon; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Glaukos Corporation; Novartis Pharmaceuticals Corporation; and Reichert, Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Alcon; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Glaukos Corporation; Novartis Pharmaceuticals Corporation; and Reichert, Inc; Contracted Research: Heidelberg Engineering GmbH; and Topcon Medical Systems, Inc.
Murray Fingeret, OD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Allergan; Bausch & Lomb Incorporated; Carl Zeiss Meditec, Inc; Glaukos Corporation; Heidelberg Engineer GmbH; Ivantis Inc; and Topcon Medical Systems, Inc.
Louis R. Pasquale, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Bausch & Lomb Incorporated; Eyenovia, Inc; Nicox; and Verily Life Sciences LLC.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 65781-GL (Enduring Distance Learning)
COPE Course Category: Glaucoma
Disclosure of Commercial Support
This continuing education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.
This continuing education activity is copyrighted to MedEdicus LLC ©2019. All rights reserved. 188
- 1.00 COPE
Clicking Register indicates that you have reviewed the CE information for this activity.
Learning Method and Medium
This educational activity consists of a webcast and ten (10) study questions. The participant should, in order, read the learning objectives, view the webcast, answer all questions in the posttest, and complete the evaluation. To receive credit for this activity, please complete the posttest and evaluation. This educational activity should take a maximum of 1.0 hour to complete.